CCN2 and postmenopausal osteoporosis: All three are approved for the treatment of postmenopausal osteoporosis in women at high risk for fracture.[44, 45, 46] Our series of studies studying the effect of CCN2 inhibition in neuromusculoskeletal tissues was performed using young, female Sprague–Dawley rats.